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Reconstitution of CD39 in liposomes amplifies
nucleoside triphosphate diphosphohydrolase
activity and restores thromboregulatory properties
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Elliot L. Chaikof, MD, PhD,a,c Atlanta, Ga; and Boston, Mass
Background: CD39 (nucleoside triphosphate diphosphohydrolase [NTPDase-1]) expressed on the luminal surface of
endothelial cells rapidly metabolizes extracellular adenosine triphosphate (ATP) and adenosine diphosphate (ADP) to
adenosine monophosphate (AMP), and abrogates platelet reactivity. Optimization of CD39 enzymatic activity appears
dependent upon the expression of both transmembrane domains within plasma membranes. Thus, motivation exists to
examine therapeutic antiplatelet formulations that consist of liposomal CD39.
Methods: Full-length human CD39 was produced by using a yeast expression system, purified, and reconstituted within
lipid vesicles. The catalytic efficiency (kcat/Km) of CD39-mediated phosphohydrolysis of ADP and ATP was determined
both for detergent-solubilized and protein-reconstituted CD39 within lipid membranes. The capacity of CD39-
containing lipid vesicles to inhibit platelet activation induced by ADP, collagen, or thrombin was determined in vitro by
platelet aggregometry. A murine model of thromboplastin-induced thromboembolism was used to determine the
effectiveness of intravenous liposomal CD39 in limiting platelet consumption and mortality.
Results: Reconstitution of human CD39 in lipid vesicles was associated with a decrease in Km of nearly an order of
magnitude over the detergent-solubilized form. There was a concomitant increase in both ADPase and ATPase catalytic
efficiencies (kcat/KmADPase: sol CD39: 2.7 106 vs liposomal CD39: 1.4 107min/M; kcat/KmATPase: sol CD39:
7.2  106 vs liposomal CD39: 2.0 107 min/M). Furthermore, CD39 lipid vesicles effectively inhibited platelet
aggregation when activated by ADP, collagen, or thrombin, and also promoted platelet disaggregation (60.4%  6.1%).
Treatment with CD39 lipid vesicles preserved platelet counts after thromboplastin injection (pretreatment, 906.8 42.9
platelets/m3; empty vesicles, 278.6  34.8 platelets/m3; CD39 vesicles, 563.6  42.2 platelets/m3; n  10
mice/test group; P < .0001). In parallel survival studies, liposomal CD39 reduced mortality from 73% to 33% (P < .05;
n  12 mice/experimental test group, n  15 mice/control test group).
Conclusions: Incorporation of solubilized CD39 into a lipid bilayer restores enzyme activity and optimizes thromboregu-
latory potential. Treatment with CD39 in liposomal formulations decreased mortality in a murine model of thrombo-
plastin-induced thromboembolism by limiting intravascular platelet aggregation and thrombosis. ( J Vasc Surg 2006;43:
816-23.)
Clinical Relevance: Platelets express at least three distinct purinergic receptors that bind ADP, only one of which is
blocked by oral thienopyridine derivatives, such as clopidogrel. In this report, we demonstrate that CD39 liposomal
formulations rapidly metabolize ADP to AMP and effectively inhibit platelet activation and aggregation in vitro and in
vivo. CD39 liposomal formulations may provide a useful therapeutic option either alone or in combination with other
existing antiplatelet regimens to treat acute vascular syndromes characterized by platelet thrombus formation, such as
stroke or acute lower-extremity ischemia.CD39 (ectonucleoside triphosphate diphosphohydro-
lase [E-NTPDase-1]) is expressed on the luminal surface
and caveolar microdomains of quiescent endothelial
cells,1,2 rapidly metabolizes adenosine triphosphate (ATP)
and adenosine diphosphate (ADP) to adenosine mono-
phosphate (AMP), and reduces platelet reactivity to most
agonists, even in the absence of prostacyclin or nitric ox-
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816ide.1,3,4 By reducing local concentrations of ATP and ADP,
CD39 represents a physiologically important antithrom-
botic mechanism, not only by blocking platelet aggregation
and recruitment but also by further limiting additional
endothelial cell- and leukocyte-mediated procoagulant
events.5,6 In support of the central role of CD39 in regu-
lating hemostasis and thrombus formation, Pinsky et al7
and Enjyoji et al8 have noted that CD39-null mouse lines
are exquisitely sensitive to vascular injury.
We have further reported that induced downregulation
of CD39 by proinflammatory stimuli or balloon injury
leads to an increase in platelet aggregation and thrombus
formation.9-11 Similarly, the generation of a mouse model
that overexpresses human CD39 resulted in impaired plate-
let aggregation12 and prolonged bleeding times,12 and that
agents that maintain CD39 expression, such as 3-hydroxy-
3-methylgluatryl coenzyme A (HMG-CoA) reductase in-
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Recombinant, soluble, truncated forms of human CD39
and related NTPDases have been produced and their ca-
pacity to inhibit platelet aggregation and related throm-
botic events demonstrated in vivo.7,14-17
CD39 consists of a large extracellular domain flanked
by one amino-terminal and one carboxy-terminal transmem-
brane domain, each of which has a small cytoplasmic tail. 18
The active site is thought to reside in the extracellular domain,
as based on the presence of five apyrase conserved regions that
are shared with other members of the NTPDase family.19-23
Although the specific functions of the apyrase conserved
regions are unknown, their homology to the phosphate-
binding domains of the actin-HSP70 ATPase superfamily19
suggests that these sites are responsible for phosphate bind-
ing and hydrolysis.
Despite reports of functionally active truncated ver-
sions of CD39, the effectiveness of soluble CD39 has been
limited by a dramatic decrease in biochemical activity com-
pared with its membrane-associated intact counterpart.
Significantly, the biologic activity of this protein appears
intimately tied to the presence of both transmembrane
domains. For example, initial reports demonstrated that
ectonucleotidase activity of cell membrane fractions de-
creased upon solubilization with most detergents.24,25
Wang et al25 subsequently showed that enzymatic activity
was significantly decreased in CD39 mutants lacking either
the first or second transmembrane domains or in double-
truncated mutants compared with the activity expressed in
cell membrane fractions.20
Notably, a recent report demonstrates that CD39’s
transmembrane domains regulate activity through highly
dynamic intra- and intersubunit interactions.26 Moreover,
Papanikolaou et al27 have also demonstrated that interfer-
ing with cholesterol levels by using drugs that either deplete
or sequester membrane cholesterol results in a strong inhi-
bition of the enzymatic and antiplatelet activity of CD39.
Thus, optimization of CD39 antithrombotic activity ap-
pears to depend on its localization as a full-length protein in
the cell membrane. Given these observations, we sought to
examine liposomal formulations that consist of CD39 inte-
grated within lipid bilayers.
To our knowledge, this report is the first to describe the
purification of the full-length human CD39 by using a
Pichia yeast expression system, with reconstitution within
lipid vesicles. Significantly, the catalytic efficiency (kcat/
Km) of solubilized CD39 was restored when it was recon-
stituted within a lipid membrane.Moreover, the capacity of
CD39-containing lipid vesicles to inhibit platelet aggrega-
tion induced by ADP, collagen, or thrombin is demon-
strated. Finally, intravenous delivery of CD39 incorporated
into liposomes reduced mortality in a murine model of
tissue factor-induced thromboembolism by limiting intra-
vascular platelet aggregation and thrombosis.
MATERIALS AND METHODS
CD39 expression. The plasmid carrying the CD39
human coding sequence was generated as detailed else-where.1,20 Polymerase chain reaction (PCR) was used to
add a Kozak consensus sequence (ANNATGG) flanked by
EcoRI to the 5= end of CD39 and a FLAG tag
(DYKDDDDK) flanked by XbaI to the 3= end of CD39.28
The construct was harbored in pCR 2.1-TOPO (Invitro-
gen, San Diego, Calif) and multiplied in One Shot Top10
(Invitrogen). To express CD39 in yeast, the EcoRI/XbaI
digestion product was cloned into pPICZ (Invitrogen) and
transformed into Pichia pastoris strain SMD1168 (Invitro-
gen). The expression construct was confirmed through
DNA sequencing analysis. P. pastoris cultures were grown
at 30°C in BMGY medium (1% yeast extract, 2% peptone,
100 mM potassium phosphate, pH 6.0; 1.34% yeast nitro-
gen base, 4  10-5% biotin, 1% glycerol). Expression was
induced for 4 days with 0.5% methanol.
Protein preparation. Cells were harvested (1000g, 5
minutes, 4°C), resuspended in breaking buffer (20 mM
Tris-Cl, pH 7.5; 1 mM EDTA, 5% glycerol), and then
disrupted in a BeadBeater (BioSpec, Bartlesville, Okla).
Cell lysates were centrifuged (100,000g, 60 minutes, 4°C)
to separate membrane and soluble fractions. Western blot
analysis revealed all native CD39 to be expressed exclusively
in yeast membrane fractions. CD39 was extracted from
membrane fractions by using 0.5% Triton X-100 and puri-
fied by using anti-FLAGM2 affinity chromatography accord-
ing to manufacturer’s instructions (Sigma, St. Louis, Mo).
Protein concentrationwas determinedwith the Bradford Pro-
tein Assay (BioRad, Hercules, Calif). Excess detergent was
removed by using hydrophobic interaction chromatography
(Biobeads, BioRad) before incorporation of CD39 into lipid
vesicles.
Sodium dodecyl sulfate polyacrylamide gel electro-
phoresis/Western blot analysis. Sodium dodecyl sulfate
(SDS) polyacrylamide gel electrophoresis was performed
according to Laemmli.29 Samples (5 to 10 g/well) were
boiled in Laemmli sample buffer (BioRad) and separated
on 10% acrylamide-SDS gels. Total protein was visualized
with Coomassie G250 (BioRad). Western blot analysis was
performed by using commercial mouse monoclonal anti-
bodies to native CD39 (BU61, AnCell Co, Bayport,
Minn). Bands were visualized by using the ECL plus West-
ern blotting detection kit (Amersham Biosciences, Buck-
inghamshire, UK). Internal amino acid sequencing was
used to confirm the expression of CD39. N-linked sugars
were removed from purified protein using PNGaseF ac-
cording to manufacturer’s instructions (Sigma). The deg-
lycosylated product was analyzed by Western blot.
Incorporation of CD39 into lipid vesicles. Large
unilamellar vesicles of 12 mM 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine (POPC) (Avanti Polar Lipids,
Inc., Alabaster, Ala) lipid solution in TBS (20 mM Tris-Cl,
100 mM sodium chloride, pH 7.4) were prepared by four
successive freeze/thaw/vortex cycles using liquid nitrogen
and a 45°C water bath. CD39 (1.4108 mol) was added
and the lipid/CD39 solution was gently mixed for 1 hour
at room temperature before it was extruded 21 times, each
through two back-to-back 2000 nm and then 600 nm
glyco
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a similar manner without the addition of ectonucleotidase.
Biochemical characterization. CD39 activity was
measured at 37°C in 300 L of activity buffer (50 mM
Tris-Cl, pH 8.0; 120 mM sodium chloride, 5 mM potas-
sium chloride, 5 mM calcium chloride). The reaction was
started by the addition of 3 to 300 M of substrate nucle-
otide. Inorganic phosphate was measured as described by
Ames.30 Vesicle turbidity was eliminated by boiling reac-
tion samples in 1% (w/v) SDS prior to incubation in Ames
reagent. Background values were obtained in the absence
of enzyme and/or calcium chloride. Kinetic constants were
determined by measuring initial rates of reaction (mol
Pi/min), using the Michaelis-Menton equation for the
determination of Km and kcat.
Platelet aggregation. The Emory University Institu-
tional Review Board approved all studies with human
blood. Blood was taken after informed consent from
healthy human volunteers and anticoagulated with 0.1
volume 3.8% sodium citrate. Platelet-rich plasma (PRP)
was prepared by centrifugation of whole blood (900g, 10
minutes, 25°C). PRP was removed and the remaining
blood sample was centrifuged (2000g, 10 minutes, 25°C)
to isolate platelet-poor plasma. Aggregation studies were
performed on a four-channel PAP-4 Platelet Aggregation
Profiler (Bio/Data Corp, Horsham, Penn). PRP contain-
ing 4.6  107 platelets was incubated in an aggregometer
cuvette at 37°C for 3 minutes with various concentrations
of CD39 lipid vesicles, empty lipid vesicles, or saline. All
sample volumes were adjusted to 270 L with saline when
necessary. After the incubation period, agonist (ADP, col-
lagen, thrombin) was added to the cuvette at the concen-
trations indicated and changes in light transmission were
monitored for 5 to 6 minutes. Platelet disaggregation stud-
ies were performed by initiating aggregation with 5 M
ADP followed by addition of enzyme at the concentration
indicated at 1 minute.17
In vivo thrombosis model. The Emory University
Institutional Animal Care and Use Committee approved all
animal studies. Male C57BL/6 mice (Charles River Labo-
ratory, Wilmington, Mass), weighing 20 to 25 g, were
Fig 1. A, Coomassie staining of affinity-purified CD39
B, Western immunoblot analysis confirms the expression
54 kDa native CD39 product was observed following deanesthetized by a 150-L intramuscular injection of amixtureof 0.2% xylazine base and 1% ketamine in phosphate-buffered
saline. The jugular veins were exposed surgically, and CD39
lipid vesicles (8 mg/kg CD39) or empty lipid vesicles were
administered intravenously 2 minutes before induction of
thrombosis. For platelet consumption studies, blood was
collected 2 minutes after thromboplastin injection at 65
L/kg and anticoagulated with 0.1 volume 3.2% sodium
citrate. Platelets were counted on an Ac-T 10 Hematology
Analyzer (Beckman Coulter, Inc., Fullerton, Calif). For
survival studies, human thromboplastin (Dade Behring,
Marburg, Germany), reconstituted according to manufac-
turer’s instructions, was injected at 140 L/kg in the
contralateral jugular vein over a period of 3 to 4 seconds.
Mice were observed up to 30 minutes, although death in
the untreated group typically occurred within 3 to 7 min-
utes.
The Student’s two-tailed unpaired t test was used to
evaluate significance of the differences in platelet count.
The 2 was used to determine significance of the differences
in mortality assays.
Lung histology. Lungs were removed 2 minutes after
injection of thromboplastin (65 L/kg) and fixed in 4%
formaldehyde. Paraffin sections (5 m thick) were stained
with hematoxylin and eosin. In all cases, five fields were
examined (100), and identifiable occluded vessels were
counted in each field.31 Lung histology was performed in
five experimental and five control mice.
RESULTS
Synthesis of recombinant CD39 and reconstitution
in lipid vesicles. CD39 was extracted and affinity-purified
from yeast membrane fractions with an overall yield of 5
mg/L in the final purified product. Coomassie staining
revealed one strong band migrating at approximately 70
kDa and Western immunoblot analysis confirmed that this
band represented CD39 (Fig 1). The 54 kDa native CD39
product was observed after treatment with peptide N-
glycosidase F (Fig 1).
Kinetic parameters were measured for both detergent-
solubilized CD39 and for protein reconstituted in POPC
lipid vesicles. As summarized in the Table, reconstitution of
ls one strong band migrating at approximately 70 kDa.
D39 with a 70 kDa band recognized by BU61. C, The
sylation.revea
of CCD39 in lipid vesicles is associated with a reduction of Km of
a (R
1:857
JOURNAL OF VASCULAR SURGERY
Volume 43, Number 4 Haller et al 819nearly an order of magnitude with a concomitant increase in
both ADPase and ATPase catalytic efficiency (ie, kcat/Km).
Likewise, reaction rates were significantly enhanced when
CD39 was reconstituted within liposomes, particularly in
the physiologically relevant ADP concentration range of 0
to 10 M (Fig 2). Kinetic parameters were not influenced
upon varying the CD39-to-lipid molar ratios in a range
between 1:8570 and 1:857.
Blockade of ADP, collagen, and thrombin-induced
platelet aggregation in vitro by CD39-containing lipid
vesicles. CD39 lipid vesicles effectively inhibited platelet
aggregation when platelets were activated with 10 M
ADP, 5 g/mL collagen, or 0.1 U/mL thrombin (Fig 3).
Disaggregation studies were also performed by initiating
platelet aggregation with 5 M ADP followed by the
addition of CD39 lipid vesicles at 1 minute. Notably, the
addition of CD39 lipid vesicles to aggregating platelets
produced a 60.4%  6.1% (mean  SD) disaggregation
response (n  4) (Fig 4).
Inhibition of in vivo thrombosis byCD39-containing
lipid vesicles. The ability of CD39-containing lipid vesicles
to inhibit thrombus formation in vivo was evaluated in a





Km (M) 66.9 40.3
kcat/Km (min/M) 2.7  106 7.2  10
ADPase, Adenosine diphosphatase; ATPase, adenosine triphosphatase; POP
N  3; SE 5%. Values determined by linear regression of transformed dat
*Data illustrated for vesicles consisting of a molar ratio of CD39:POPC of
Fig 2. Substrate concentration dependence of adenosine diphos-
phatase (ADPase) activity by detergent solubilized CD39 (Œ) and
liposome-incorporated CD39 (●). Values were normalized to rates
obtained with 300 M adenosine di phosphate (ADP). Data are
average values from three independent experiments (standard er-
rors 5%).murine pulmonary thromboembolism model where intra-venous injection of thromboplastin induces systemic
thrombotic responses. In platelet consumption studies,
platelet counts were dramatically reduced after thrombo-
plastin injection due to systemic platelet activation, aggre-
gation, and thrombus formation (Fig 5). Treatment with
CD39 lipid vesicles significantly limited the reduction in
platelet counts (n  10 mice/test group; P  0.0001). In
survival studies, treatment with CD39 reduced mortality
from 73% to 33% (P .05; n 12 mice/experimental test
group, n  15 mice/control test group) (Fig 6). Histologic
examination revealed thrombosis of many small vessels in
the control group, with an average of 12  3 occluded
vessels per high power field vs 4 1 in the CD39 treatment
group (P  .05) (Fig 6).
DISCUSSION
Multicenter randomized clinical trials have shown that
intravenous agents that inhibit platelet activation and ag-
gregation, such as IIb/	III-receptor antagonists, have a
beneficial effect in percutaneous coronary interventions
and improve long-term survival.32-36 Nonetheless, recog-
nized drawbacks of IIb/	III-receptor antagonists include
dose limitations that often lead to inadequate platelet inhi-
bition as well as paradoxical partial agonist effects that lead
to platelet activation and platelet-mediated inflamma-
tion.37,38 To compensate for these effects, combination
therapy with P2Y12-receptor antagonists that block plate-
let responses to ADP, such as the oral thienopyridine
derivative clopidogrel, has been advocated.39
ADP release from platelet granules is integral to ampli-
fying and propagating platelet activation, aggregation, and
recruitment in response to a variety of initiating stimuli. 1,40-42
Although the clinical benefits of thienopyridine derivatives
have been demonstrated,43-48 Gurbel et al49 have demon-
strated that the normal dosing regimen of clopidogrel
blocks less than 40% of ADP-induced platelet aggregation
and is highly variable between individuals. These data em-
phasize that platelets express at least three distinct puriner-
gic receptors that bind ADP, only one of which is blocked
by clopidogrel.
Recent reports have described the generation of soluble
human CD39 and apyrase mutants that exhibit ADPase
activity and limit platelet activation and aggregation.7,14-17
By removal of extracellular ATP and ADP, pharmacother-
apeutics based upon CD39 limit activation of platelet re-
ceptors P2Y1 and P2X1, in addition to P2Y12. In addition,
and liposome reconstituted CD39
CD39 in POPC vesicles:
ATPase activity*
CD39 in POPC vesicles
ATPase activity*
9.6 7








2through the phosphohydrolysis of ATP and ADP to AMP,
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potent antiplatelet and anti-inflammatory activities. Of
note, treatment with soluble CD39 improves neurologic
outcome and reduces infarct size in a murine stroke
Fig 3. Inhibition of platelet aggregation by CD39 lipid vesicles.
A, Platelets were activated with 10 M adenosine diphosphate,
final CD39 concentration is 2.1  107 M; (B) 5 g/mL colla-
gen, final CD39 concentration is 5.3  107 M; (C) 0.1 U/mL
thrombin, final CD39 concentration is 1.1  106 M. Represen-
tative data sets are presented (n  4). PRP, Platelet-rich plasma.model.7,16,50 Moreover, in an in vitro model, solubleCD39 inhibited platelet deposition on synthetic vascular
prostheses to a greater extent than that of heparin alone.51
Despite encouraging results with this use of truncated
forms of CD39, considerable evidence supports a critical
role for both the N- and C-terminal transmembrane do-
mains and their localization within lipid assemblies in max-
imizing the activity of the CD39 catalytic domain.24-27
Thus, motivation exists for investigating the activity of
CD39 in a system in which the entire transmembrane
protein is reconstituted within well-defined lipid vesicles.
Fig 4. CD39 lipid vesicles promote platelet disaggregation.
CD39 lipid vesicles (7.9  107 M final CD39 concentration)
were added to plasma-rich platelets 1 minute after the addition of
5 M adenosine diphosphate (ADP). Representative data set is
presented (n  4).
Fig 5. Platelet counts after thromboplastin injection. Results are
mean platelet count  SEM. White bar, control mice receiving
empty vesicle injection 2 minutes before blood draw (n  10).
Black bar, mice receiving CD39 vesicle treatment 2 minutes before
thromboplastin (65 L/kg) injection (n  10). Grey bar, mice
receiving empty vesicle treatment 2minutes before thromboplastin
(65 L/kg) injection (n  10). TF, tissue factor.All told, we postulated that liposomal formulations of
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menting other existing antiplatelet therapies directed at
acute vascular syndromes characterized by platelet throm-
bus formation. In principle, formulations of greater po-
tency should result in significant dose reductions. More-
over, controlling lipid vesicle composition is an additional
variable to assist in tailoring the circulating half-life of the
drug as well as in the design of site-directed therapies.
As evident from our investigations, the incorporation
of CD39 into the lipid membrane of vesicles significantly
enhances NTPDase enzyme activity compared with its sol-
ubilized counterpart. Specifically, ADPase and ATPase cat-
alytic efficiencies (kcat/Km) were increased fivefold and
threefold, respectively. This effect was statistically signifi-
cant. Of note, the ADPase activity (kcat/Km) of liposome-
reconstituted CD39 exceeded that recently reported for a
variety of recombinant human apyrase constructs by two-
fold to 500-fold.17
Admittedly, an increase in catalytic activity has been
observed in selected cases for certain membrane-bound
proteins when incorporated within liposomes, such as
thrombomodulin. Typically, this effect is a consequence of
a reduction in Km that is most commonly attributed to an
enhanced capacity of the enzyme substrate to bind to the
lipid membrane, which leads to a dramatic increase in local
substrate concentration. In other words, the membrane
serves as a sink, concentrating fluid phase substrates within
the two-dimensional plane of the lipid bilayer. In these
instances, the enzyme substrate often has a structural fea-
ture(s) that enhance its binding to the lipid bilayer. For
example, the Gla domain is responsible for this effect in
protein C interactions with membrane bound thrombo-
modulin.52 ADP and ATP have no known structural fea-
tures that enhance binding to a lipid membrane. Moreover,
the catalytic site of CD39 is localized entirely to the extra-
cellular portion of the protein. Thus, these data support the
notion that the transmembrane domains of CD39, when
localized to the lipid bilayer, induce a conformation change
in CD39 that leads to increased catalytic efficiency. To our
knowledge, this report is the first to note such an effect in
an isolated cell-free system and the first to characterize the
Fig 6. A, Mortality after thromboplastin injection. Bla
mice receiving empty lipid vesicles (n  15); P  .0
hematoxylin and eosin frommice receiving thromboplast
or (C)CD39. Pulmonary thrombi (black arrows)were ob
occurrence among mice treated with CD39 (P  .05).magnitude of this effect.Notably, CD39 liposomes inhibited in vitro platelet
activation when induced by thrombin, ADP, or collagen.
Moreover, when CD39 liposomes were added one minute
after the initiation of platelet aggregation by ADP, nearly
two thirds of the platelet aggregates were disassociated. In
this regard, it bears emphasis that cyclooxygenase inhibi-
tors, such as aspirin or indomethacin, reduce the extent of
platelet aggregation but do not mediate platelet disaggre-
gation.15
The efficacy of liposomal formulations of CD39 was
further confirmed in vivo by a dramatic improvement in
survival outcome in a model of thromboplastin-induced
pulmonary thromboembolism. That this effect can be at-
tributed to a reduction in intravascular thrombosis is sup-
ported both by histologic confirmation of a fewer intravas-
cular pulmonary thrombi and by an observed reduction in
systemic platelet consumption.
CONCLUSION
These data provide motivation for the initiation of
clinical studies to assess whether liposomal formulations of
CD39 will improve the clinical efficacy of IIb/	III-receptor
antagonists. Furthermore, given the central role of CD39
as a pluripotent inhibitor of multiple pathways leading to
platelet activation and vascular thrombosis, these formula-
tions may prove to be clinically effective as a single-agent
therapy in the treatment of a variety of acute thrombotic
events.
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